A drug-repurposing screen has identified the anticoagulant dabigatran as a potential disease-modifying candidate for osteoarthritis, with preclinical data suggesting the compound can reduce joint pain and slow cartilage degeneration.

An approved blood-thinning medication has shown potential to reduce joint pain and slow cartilage degeneration in animal models of osteoarthritis, by targeting two molecules associated with the condition’s underlying inflammation.
The findings, based on experiments in mice and non-human primates, suggest that dabigatran could offer a new approach to treating osteoarthritis by targeting two inflammatory pathways simultaneously. The research could help address the lack of disease-modifying treatments capable of slowing or halting the condition’s progression.
Osteoarthritis is a leading cause of pain and disability worldwide, and although traditionally associated with the gradual breakdown of joint cartilage, growing evidence is connecting its progression to chronic low-grade inflammation.
Two molecules suspecting to be involved in this process are tumour necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β). Both contribute to inflammatory signalling involved in joint tissue damage.
While treatments targeting each molecule individually have been investigated, these approaches have so far produced poor results in clinical trials.
Targeting two inflammatory pathways
Researchers led by Wenyu Fu at the Yale School of Medicine hypothesised that simultaneously suppressing TNF-α and IL-1β could produce stronger therapeutic effects than targeting either molecule alone.
To investigate this, the team screened a library of US Food and Drug Administration-approved medicines for compounds capable of inhibiting both inflammatory signalling pathways in human cartilage-producing cells.
The screening identified dabigatran, an anticoagulant commonly used to prevent blood clots, as a good candidate for testing. The researchers then administered the drug in mouse and macaque models of osteoarthritis, and in both models, it reduced pain and slowed cartilage degeneration in the affected joints.
These findings suggest that the medication could influence both the symptoms and structural progression of osteoarthritis, rather than simply providing pain relief.
How dabigatran works
Follow-up experiments helped reveal how the drug affects the inflammatory pathways, with the researchers observing that dabigatran binds to a protein called BIG2, which regulates cellular processes involved in inflammatory signalling.
Through this interaction, dabigatran indirectly reduced the activity of TNF-α while increasing the degradation of the receptor for IL-1β. By influencing both pathways through BIG2, the drug appeared to suppress two important drivers of osteoarthritis-related inflammation.
This suggests that BIG2 could be potential therapeutic target and modulating its activity could provide an alternative approach to developing treatments for inflammatory joint disease.
Further research needed
Despite the promising results, the researchers cautioned that further investigation will be needed before dabigatran could be considered as an osteoarthritis treatment.
In particular, its anticoagulant properties present a potential safety concern. As a blood-thinning medication, dabigatran increases the risk of bleeding, meaning its suitability for treating a chronic condition such as osteoarthritis will need careful assessment.
The researchers suggest that developing and refining compounds that retain the drug’s ability to target BIG2 without unwanted anticoagulant effects could offer a route towards safer treatments.
The findings provide a potential new direction for osteoarthritis drug discovery, although further studies will be required to establish whether this approach can translate into an effective treatment for patients.



No comments yet